These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2015-002070-21 Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor 2019-01-02 due-trials
Other 2019-001043-41 A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinu... not-yet-due
Reported results 2019-003898-26 A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE MASS BALANCE, ROUTE OF ELIMINATION, AND METABOLIC PROFILE OF [14C] LABELED MGCD516 MALATE SALT IN HEALTHY MALE SUBJECTS 2020-02-03 due-trials
Ongoing 2020-003101-58 A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation not-yet-due
Ongoing 2020-003645-11 A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation not-yet-due
Ongoing 2020-004048-27 A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standar... not-yet-due